vTv Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $36 price target The company’s lead asset, cadisegliatin, activates glucokinase, a clinically and commercially validated target for the treatment of diabetes as an insulin adjuvant with approval in China of dorzagliatin in type 2 diabetes, the analyst tells investors in a research note. The firm says vTv can now continue to enroll patients in the Phase 3 trial, which is evaluating similar endpoints to the Phase 2 trial, increasing its confidence in success.